Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good Sells 25,037 Shares of Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 25,037 shares of Trevi Therapeutics stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $2.86, for a total value of $71,605.82. Following the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $610,075.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Trevi Therapeutics Price Performance

TRVI stock opened at $2.65 on Thursday. The company has a 50 day moving average price of $3.00 and a 200 day moving average price of $2.13. Trevi Therapeutics, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $4.00. The stock has a market capitalization of $186.64 million, a PE ratio of -7.79 and a beta of 0.91.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. As a group, equities analysts expect that Trevi Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TRVI shares. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Oppenheimer reissued an “outperform” rating and issued a $9.00 target price on shares of Trevi Therapeutics in a report on Thursday, March 21st.

Institutional Trading of Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. grew its holdings in shares of Trevi Therapeutics by 7.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after buying an additional 500,000 shares during the period. Opaleye Management Inc. boosted its stake in Trevi Therapeutics by 48.6% in the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after purchasing an additional 829,100 shares during the period. Vanguard Group Inc. boosted its stake in Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after purchasing an additional 60,249 shares during the period. Silverarc Capital Management LLC boosted its stake in Trevi Therapeutics by 4.7% in the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after purchasing an additional 41,491 shares during the period. Finally, Propel Bio Management LLC acquired a new position in Trevi Therapeutics in the 1st quarter worth $897,000. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.